Sign up

RTW Investments, LP

$11.7B assets · 84 holdings · Q2 2026 · Filed 14 AUG 2026

About RTW Investments, LP’s 13F portfolio

RTW Investments, LP is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , RTW Investments, LP reported $11.7B across 84 US-listed positions (). Its largest position is MADRIGAL PHARMACEUTICALS INC (MDGL) at 9.1% of the reported book, and its ten biggest holdings make up 48% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.

$11.7B
Assets (13F)
#432
of 8,839 by size
84
Holdings
48%
Top-10 weight
35
Buys
21
Sells
Top holdings · Q2 2026
84 total
#StockPrice% of portfolioSharesValue
1
NASDAQ: MDGL
MADRIGAL PHARMACEUTICALS INC
—
—
9.1%
2.0M$1.1B
2
NASDAQ: ARGX
ARGENX SE
—
—
5.6%
709K$658.2M
3
NASDAQ: PTCT
PTC THERAPEUTICS INC
—
—
5.4%
7.7M$631.9M
4
NASDAQ: PTGX
PROTAGONIST THERAPEUTICS INC
—
—
5.3%
5.1M$620.4M
5
NASDAQ: CGON
CG ONCOLOGY INC
—
—
5.2%
8.5M$605.0M
6
NASDAQ: INSM
INSMED INC
—
—
4.4%
4.8M$516.3M
7
NASDAQ: TNGX
TANGO THERAPEUTICS INC
—
—
3.7%
13.9M$434.5M
8
NASDAQ: SYRE
SPYRE THERAPEUTICS INC
—
—
3.2%
4.3M$377.5M
9
NASDAQ: CELC
CELCUITY INC
—
—
3.0%
3.3M$345.8M
10
NASDAQ: ERAS
ERASCA INC
—
—
2.8%
17.9M$328.8M
11
NASDAQ: RDNT
RADNET INC
—
—
2.6%
4.8M$298.9M
12
NASDAQ: ORKA
ORUKA THERAPEUTICS INC
—
—
2.6%
3.1M$298.7M
13
NASDAQ: NTRA
NATERA INC
—
—
2.3%
1.0M$271.4M
14
NASDAQ: RARE
ULTRAGENYX PHARMACEUTICAL IN
—
—
2.2%
7.8M$260.3M
15
NASDAQ: IRTC
IRHYTHM HOLDINGS INC
—
—
2.2%
2.2M$259.6M
16
NASDAQ: CYTK
CYTOKINETICS INC
—
—
2.1%
2.9M$243.8M
17
NASDAQ: KLRA
KAILERA THERAPEUTICS INC
—
—
2.0%
10.8M$237.4M
18
NASDAQ: ESTA
ESTABLISHMENT LABS HLDGS INC
—
—
1.9%
2.7M$227.9M
19
NASDAQ: GH
GUARDANT HEALTH INC
—
—
1.9%
1.5M$222.2M
20
NASDAQ: NBIX
NEUROCRINE BIOSCIENCES INC
—
—
1.8%
1.3M$213.7M
21
NASDAQ: TARS
TARSUS PHARMACEUTICALS INC
—
—
1.8%
3.4M$211.3M
22
NASDAQ: STOK
STOKE THERAPEUTICS INC
—
—
1.6%
5.6M$184.0M
23
NASDAQ: QURE
UNIQURE NV
—
—
1.5%
3.9M$181.5M
24
NASDAQ: ACAD
ACADIA PHARMACEUTICALS INC
—
—
1.5%
7.1M$180.8M
25
NASDAQ: RGEN
REPLIGEN CORP
—
—
1.4%
1.2M$169.3M

Showing 1–25 of 84 positions on this page reported in this 13F.

Sector allocation
  • Healthcare97%
  • Financial Services0.1%
Recent activity · vs 2026-03-31
Bought35
  • AddedPTGXPROTAGONIST THERAPEUTICS INC+0.0%$620.4M
  • AddedCGONCG ONCOLOGY INC+21.9%$605.0M
  • AddedTNGXTANGO THERAPEUTICS INC+4.5%$434.5M
  • AddedSYRESPYRE THERAPEUTICS INC+1.9%$377.5M
  • AddedCELCCELCUITY INC+8.7%$345.8M
  • AddedERASERASCA INC+11.1%$328.8M
  • AddedRDNTRADNET INC+13.1%$298.9M
  • AddedORKAORUKA THERAPEUTICS INC+52.5%$298.7M
  • AddedRAREULTRAGENYX PHARMACEUTICAL IN+114%$260.3M
  • AddedIRTCIRHYTHM HOLDINGS INC+30.8%$259.6M
Sold21
  • ReducedNTRANATERA INC−20.0%$271.4M
  • ReducedTSHATAYSHA GENE THERAPIES INC−0.9%$92.3M
  • ReducedCOGTCOGENT BIOSCIENCES INC−57.7%$89.4M
  • ReducedHNGEHINGE HEALTH INC−74.1%$41.5M
  • ReducedBBNXBETA BIONICS INC−25.0%$23.5M
  • ReducedHTFLHEARTFLOW INC−40.4%$8.7M
  • ReducedAVTXAVALO THERAPEUTICS INC−79.6%$3.2M
  • ReducedXGNEXAGEN INC−50.7%$907K
  • SoldAPLSAPELLIS PHARMACEUTICALS INC−100%—
  • SoldISRGINTUITIVE SURGICAL INC−100%—
5%+ Beneficial Ownership Stakes · 2 activist (13D) · 26 passive (13G)

Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.

#StockType% of classSharesFiled
1
OBIO
ORCHESTRA BIOMED HOLDINGS, INC.
13D19.7% · 2 classes11.9MFiled 25 FEB 2026
2
STOK
Stoke Therapeutics, Inc.
13G10.0% · 2 classes5.3MFiled 14 FEB 2025
3
ESTA
Establishment Labs Holdings Inc.
13G10.0%2.8MFiled 14 FEB 2025
4
CMPS
COMPASS Pathways plc
13G9.9% · 2 classes9.5MFiled 14 AUG 2025
5
VSTM
Verastem, Inc.
13G9.9% · 2 classes9.0MFiled 15 MAY 2026
6
PYXS
Pyxis Oncology, Inc.
13G9.9%8.5MFiled 16 NOV 2026
7
TENX
Tenax Therapeutics, Inc.
13G9.9%651KFiled 17 FEB 2026
8
ALUR
ALLURION TECHNOLOGIES, INC.
13D9.9% · 2 classes67KFiled 02 SEP 2026
9
CGON
CG Oncology, Inc.
13G9.7%8.5MFiled 14 AUG 2026
10
IMTX
Immatics N.V.
13G9.6% · 2 classes12.9MFiled 15 MAY 2026
11
TNGX
Tango Therapeutics, Inc.
13G9.3%13.3MFiled 15 MAY 2026
12
ZLAB
Zai Lab Limited
13G9.2% · 2 classes103.5MFiled 16 NOV 2026
13
REPL
Replimune Group, Inc.
13G9.0% · 2 classes8.5MFiled 16 NOV 2026
14
GHRS
GH Research PLC
13G8.9%5.5MFiled 15 MAY 2025
15
TSHA
TAYSHA GENE THERAPIES, INC.
13G8.3% · 2 classes23.4MFiled 17 FEB 2026
16
KLRA
Kailera Therapeutics, Inc.
13G8.3%10.8MFiled 14 AUG 2026
17
TARS
Tarsus Pharmaceuticals, Inc.
13G8.1%3.4MFiled 14 AUG 2025
18
RARE
Ultragenyx Pharmaceutical Inc.
13G7.9%7.8MFiled 14 AUG 2026
19
IPSC
Century Therapeutics, Inc.
13G7.1%13.0MFiled 15 MAY 2026
20
ERAS
Erasca, Inc.
13G6.4%22.4MFiled 16 NOV 2026
21
CELC
Celcuity Inc.
13G6.3%3.0MFiled 15 MAY 2026
22
RDNT
RadNet, Inc.
13G6.2% · 2 classes4.8MFiled 14 AUG 2026
23
SYRE
Spyre Therapeutics, Inc.
13G6.2%3.6MFiled 14 FEB 2025
24
QURE
uniQure N.V.
13G6.0% · 2 classes3.7MFiled 17 FEB 2026
25
—
RAPT THERAPEUTICS, INC.
13G5.9%1.6MFiled 17 FEB 2026

Showing 1–25 of 28 disclosed stakes. 6 last disclosed over a year ago (the holder may since have dropped below 5%).

Reading RTW Investments, LP’s 13F portfolio

RTW Investments, LP’s $11.7B 13F book is spread across 84 reported positions and is concentrated toward its biggest ideas, with the top ten holdings at 48%. The largest positions carry real weight, so how those names perform matters a lot to the overall book. Its five largest positions are MDGL, ARGX, PTCT, PTGX and CGON, led by MADRIGAL PHARMACEUTICALS INC (MDGL) at 9.1% of the portfolio. The heaviest sector exposure is Healthcare (97%), then Financial Services (0%).

What RTW Investments, LP changed last quarter

Between 2026-03-31 and Q2 2026, RTW Investments, LP was a net buyer: it opened 9 new positions and added to 26 more, while trimming 8 and closing 13 outright. Against a 84-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was PROTAGONIST THERAPEUTICS INC (PTGX), and its biggest reduction was NATERA INC (NTRA).

What a 13F does and doesn’t reveal

A 13F captures only RTW Investments, LP’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names RTW Investments, LP is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.

Frequently asked questions

What is an SEC 13F filing?

A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. RTW Investments, LP's profile on this page is built directly from those filings.

How current is the 13F data on RTW Investments, LP's page?

It reflects RTW Investments, LP's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When RTW Investments, LP files its next quarterly report, this page refreshes automatically.

Can I see RTW Investments, LP's complete list of holdings?

This page highlights RTW Investments, LP's largest positions rather than all 84 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under RTW Investments, LP's filings.

Does a 13F show everything RTW Investments, LP owns?

No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of RTW Investments, LP's book rather than its full strategy or total assets.

Is 13F data investment advice?

No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why RTW Investments, LP made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.

Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.